Oruka Therapeutics (ORKA) Income towards Parent Company (2010 - 2024)

Oruka Therapeutics' Income towards Parent Company history runs 15 years deep, the most recent figure standing at -$18.1 million for Q2 2024.

• In Q2 2024, Income towards Parent Company fell 1085.44% year-over-year to -$18.1 million; the TTM figure through Mar 2025 stood at -$18.1 million (down 58.4% YoY), while the FY2023 annual figure was -$60.9 million, up 5.32% from the prior year.
• Income towards Parent Company for Q2 2024 stood at -$18.1 million, down from -$7.0 million in the prior quarter.
• The five-year high for Income towards Parent Company was -$1.1 million in Q4 2023, with the low at -$18.1 million in Q2 2024.
• The 5-year median for Income towards Parent Company is -$2.8 million (2022), against an average of -$3.9 million.
• The sharpest annual moves came in 2022 and 2024: Income towards Parent Company soared 79.32% in 2022, then tumbled 1085.44% in 2024.
• Oruka Therapeutics' Income towards Parent Company stood at -$5.2 million in 2020, then retreated by 8.24% to -$5.7 million in 2021, then jumped by 79.32% to -$1.2 million in 2022, then increased by 5.03% to -$1.1 million in 2023, then slumped by 1521.35% to -$18.1 million in 2024.
• Business Quant data shows ORKA's Income towards Parent Company at -$18.1 million in Q2 2024, -$7.0 million in Q1 2024, and -$1.1 million in Q4 2023.